170 related articles for article (PubMed ID: 26153241)
21. Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure.
Deedwania P
Drugs; 2013 Sep; 73(14):1569-86. PubMed ID: 24065301
[TBL] [Abstract][Full Text] [Related]
22. Effect of ivabradine on cardiovascular outcomes in patients with stable angina: meta-analysis of randomized clinical trials.
Mengesha HG; Weldearegawi B; Petrucka P; Bekele T; Otieno MG; Hailu A
BMC Cardiovasc Disord; 2017 Apr; 17(1):105. PubMed ID: 28454527
[TBL] [Abstract][Full Text] [Related]
23. Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate.
Tagliamonte E; Cirillo T; Rigo F; Astarita C; Coppola A; Romano C; Capuano N
Adv Ther; 2015 Aug; 32(8):757-67. PubMed ID: 26293212
[TBL] [Abstract][Full Text] [Related]
24. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
Perry CM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
[TBL] [Abstract][Full Text] [Related]
25. Selective Heart Rate Reduction With Ivabradine Increases Central Blood Pressure in Stable Coronary Artery Disease.
Rimoldi SF; Messerli FH; Cerny D; Gloekler S; Traupe T; Laurent S; Seiler C
Hypertension; 2016 Jun; 67(6):1205-10. PubMed ID: 27091900
[TBL] [Abstract][Full Text] [Related]
26. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
[TBL] [Abstract][Full Text] [Related]
27. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
[TBL] [Abstract][Full Text] [Related]
28. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure.
Komajda M; Böhm M; Borer J; Ford I; Krum H; Tase A; Tavazzi L; Swedberg K
Eur J Heart Fail; 2013 Jan; 15(1):79-84. PubMed ID: 22892123
[TBL] [Abstract][Full Text] [Related]
29. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
Canet E; Lerebours G; Vilaine JP
Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
[TBL] [Abstract][Full Text] [Related]
30. [Ivabradine in patients with stable ischemic heart disease and left ventricular systolic dysfunction: the results of the BEAUTIFUL study].
Filipovský J
Vnitr Lek; 2009 May; 55(5):513-6. PubMed ID: 19514618
[TBL] [Abstract][Full Text] [Related]
31. Current Role of Ivabradine in Stable Coronary Artery Disease Without Heart Failure.
Porres-Aguilar M; Muñoz OC; Abbas A
Curr Cardiol Rep; 2016 Feb; 18(2):13. PubMed ID: 26768739
[TBL] [Abstract][Full Text] [Related]
32. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K;
Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517
[TBL] [Abstract][Full Text] [Related]
33. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.
Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
Lancet; 2008 Sep; 372(9641):817-21. PubMed ID: 18757091
[TBL] [Abstract][Full Text] [Related]
34. Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study.
Mangiacapra F; Colaiori I; Ricottini E; Balducci F; Creta A; Demartini C; Minotti G; Di Sciascio G
Clin Res Cardiol; 2017 Jan; 106(1):69-75. PubMed ID: 27520989
[TBL] [Abstract][Full Text] [Related]
35. Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction.
Heusch G; Kleinbongard P
Drugs; 2016 May; 76(7):733-40. PubMed ID: 27041289
[TBL] [Abstract][Full Text] [Related]
36. Ivabradine in chronic stable angina: Effects by and beyond heart rate reduction.
Camici PG; Gloekler S; Levy BI; Skalidis E; Tagliamonte E; Vardas P; Heusch G
Int J Cardiol; 2016 Jul; 215():1-6. PubMed ID: 27104917
[TBL] [Abstract][Full Text] [Related]
37. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease.
Gloekler S; Traupe T; Stoller M; Schild D; Steck H; Khattab A; Vogel R; Seiler C
Heart; 2014 Jan; 100(2):160-6. PubMed ID: 24186565
[TBL] [Abstract][Full Text] [Related]
38. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease.
Skalidis EI; Hamilos MI; Chlouverakis G; Zacharis EA; Vardas PE
Atherosclerosis; 2011 Mar; 215(1):160-5. PubMed ID: 21183181
[TBL] [Abstract][Full Text] [Related]
39. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
40. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population.
; Ferrari R; Ford I; Fox K; Steg PG; Tendera M
Cardiology; 2008; 110(4):271-82. PubMed ID: 18595216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
